Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Updates (CMS164) Change Review Process Meeting November 19, 2015 Jenna Williams-Bader.

Slides:



Advertisements
Similar presentations
Chapter 4: Cardiovascular Disease in Patients With CKD 2014 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
Advertisements

Screening: Doctors Paid for Heart Tests Order More NICHOLAS BAKALAR NY Times - November 14, 2011
Stages of CKD – KDOQI 2002 Definitions
MHSPHP Metrics Forum Diabetes
Redwood Community Care Organization Data Capture for ACO Quality Measures.
EHR for Meaningful Use Clinical Quality Measures Dr. Aneel Advani Associate Director for Informatics IHS Office of Information Technology Indian Health.
Aspirin Plus Coumarin Versus Aspirin Alone in the Prevention of Reocclusion After Fibrinolysis for Acute Myocardial Infarction Results of the Antithrombotics.
BETH ISRAEL DEACONNESS DATA WAREHOUSE PROJECT February 27, 2009.
Review Breast Cancer Screening Public Comment (CMS #125) and Discuss Controlling High Blood Pressure Measure Updates (CMS #165) Change Review Process Meeting.
2008 Minnesota Senior Health Options and Minnesota Senior Care/Minnesota Senior Care Plus Performance Improvement Project Care Coordinator Training March.
Component 2: The Culture of Health Care Unit 7: Quality Measurement, Performance Improvement, and Incentive Payment Schemes Lecture 4 This material was.
Quality Measurement and Improvement Component 2 / Unit 7d.
Cervical Cancer Screening Measure Updates (CMS #124)
Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,
Antidepressant Medication Management Updates (CMS128) Change Review Process Meeting November 19, 2015 Jenna Williams-Bader Anne Marie Smith Stephanie Rodriguez.
Chapter 4: Cardiovascular Disease in Patients With CKD 2015 A NNUAL D ATA R EPORT V OLUME 1: C HRONIC K IDNEY D ISEASE.
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 9: Cardiovascular Disease in Patients With ESRD.
Million Hearts Initiative, 2015 IPC Intensive, Million Hearts.
Medication Dispensed vs. Ordered Change Review Process Meeting November 19, 2015 Jenna Williams-Bader Anne Marie Smith Stephanie Rodriguez.
ENSW PTO Training Clinical Quality Measures Kyle Knierim, MD Using DARTNet to Improve Practice Wilson Pace, MD Kyle Knierim, MD 1.
Date of download: 6/3/2016 Copyright © The American College of Cardiology. All rights reserved. From: Survival of patients with diabetes and multivessel.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: Frequency and Practice-Level Variation in Inappropriate.
2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease Developed in Collaboration with.
Free Powerpoint Templates Page 1 Using Data to Guide Improvement Presented by: Brooke Thomas, Program Advisor February 28, 2013.
Date of download: 6/27/2016 Copyright © The American College of Cardiology. All rights reserved. From: Use and Outcomes of Triple Therapy Among Older Patients.
Date of download: 7/5/2016 From: Validation of the Appropriate Use Criteria for Coronary Angiography: A Cohort Study Ann Intern Med. 2015;162(8):
Date of download: 7/6/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Prognostic Importance of Physical Examination for.
Date of download: 7/7/2016 From: Management of Stable Ischemic Heart Disease: Summary of a Clinical Practice Guideline From the American College of Physicians/American.
Date of download: 9/19/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Association of Public Reporting for Percutaneous.
2016 Annual Data Report, Vol 1, CKD, Ch 4
Figure 9.1 Causes of death in ESRD patients,
Subgroup analyses for mortality after treatment with coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI). LAD, left anterior.
Copyright © 2005 American Medical Association. All rights reserved.
Chapter 8: Cardiovascular Disease in Patients with ESRD
Volume 1: Chronic Kidney Disease
Glenn N. Levine et al. JACC 2016;68:
Glenn N. Levine et al. JACC 2016;68:
Manuel Caceres, MD, Darryl S. Weiman, MD, JD 
Chapter 4: Cardiovascular Disease in Patients with CKD
New antiplatelet drugs and new oral anticoagulants
2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease  Glenn N. Levine, MD, FACC, FAHA,
Chapter 8: Cardiovascular Disease in Patients with ESRD
Focused 2012 Update of the Canadian Cardiovascular Society Guidelines for the Use of Antiplatelet Therapy  Jean-François Tanguay, MD, CSPQ, FRCPC, FACC,
Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);
Three-Year Outcomes of Multivessel Revascularization in Very Elderly Acute Coronary Syndrome Patients  Brett C. Sheridan, MD, Sally C. Stearns, PhD, Joseph.
Defining operative mortality: Impact on outcome reporting
Why surgery won the SYNTAX trial and why it matters
Kaplan-Meier curves: revascularisation rate (PCI or CABG) was significantly higher (p
Recent Temporal Changes in Atherosclerotic Cardiovascular Diseases in Ontario: Clinical and Health Systems Impact  Jack V. Tu, MD, PhD, Anam M. Khan,
Arrival Performance Acute Myocardial Infarction Patients Receiving Aspirin Within 24 Hours of Hospital Arrival Percent Jul-03.
Kaplan-Meier estimate of mortality in 1798 propensity score matched pairs with a propensity score >0.5 for the whole observational period. Kaplan-Meier.
Impact of statin therapy on patients with coronary heart disease and aortic aneurysm or dissection  Junichi Tazaki, MD, Takeshi Morimoto, MD, PhD, Ryuzo.
Perioperative cardiac events in endovascular repair of complex aortic aneurysms and association with preoperative studies  Guilherme L. Bub, MD, Roy K.
(A) Multivariable Cox regressions showing the association of higher CHA2DS2-Vasc scores (≥6) and (B) R2CHA2DS2-Vasc scores (≥7) with 1-year mortality (CABG,
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
Glenn N. Levine et al. JACC 2011;58:e44-e122
Figures showing the effects of a potential 30% relative reduction in events with next-generation drug-eluting stents in the percutaneous coronary intervention.
Antithrombotic strategies in patients on long-term oral anticoagulation therapy undergoing percutaneous coronary intervention. ACS: acute coronary syndrome;
Genetic predisposition to CHD modifies the increased CHD risk associated with smoking (*) ORs adjusted for age, gender, total energy intake, alcohol intake,
Total Arterial Off-Pump Coronary Surgery: Time to Change Our Habits?
Leslee J. Shaw et al. JIMG 2010;3:
A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.
Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.
Kaplan-Meier estimate of mortality in the two treatment strategies with significant difference between the two groups (log-rank test
Propensity score-matching
R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.
Figure 9.1.a Causes of death in ESRD patients,
Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.
Presentation transcript:

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic Updates (CMS164) Change Review Process Meeting November 19, 2015 Jenna Williams-Bader Anne Marie Smith Stephanie Rodriguez

2 IVD: Use of Aspirin or Another Antithrombotic Measure Update Revise measure to align with the HEDIS provider- level measure Measure Title: Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antiplatelet Denominator: Patients 18 years of age and older with a visit during the measurement period who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD during the measurement year (removed “discharged alive” language) Numerator: Update value set name to “Aspirin and Other Antiplatelets” Exclude patients who had documentation of use of anticoagulant medications during the measurement year

3 Current Denominator Measure intent is to capture appropriate aspirin or other antiplatelet use in adults diagnosed with certain heart conditions Denominator Statement Patients 18 years of age and older with a visit during the measurement period, and an active diagnosis of ischemic vascular disease (IVD) or who were discharged alive for acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period

4 Updated Denominator Denominator Statement Patients 18 years of age and older with a visit during the measurement period who were discharged alive who had an AMI, CABG, or PCI during the 12 months prior to the measurement year or who had a diagnosis of IVD during the measurement year The updated measure denominator removes the “discharged alive” language

5 New Exclusion Patients who had documentation of use of anticoagulant medications during the measurement year – AND: "Medication, Active: Anticoagulant Medication" overlaps "Measurement Period"

6 Next Steps: Vote Agree with proposed changes to Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic measure (CMS164)? 1.Yes 2.No Measure updates will be implemented during 2016 Annual Update